drugset
drugset / Trial / NCT07229612

A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors

NCT07229612 ↗

Phase 1/2 Not yet recruiting 200 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.

Timeline

Start
2025-11
Primary completion
2028-11
Completion
2028-11

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-4298 Unknown — —

Indications

cancer